

# ***SARS-CoV-2 UK, South African and Brazilian Variants in***

## ***Karachi- Pakistan***

Adnan Khan<sup>1</sup>, Muhammad Hanif<sup>1,2\*</sup>, Sarosh Syed<sup>2</sup>, Akhtar Ahmed<sup>1</sup>, Saqib<sup>1</sup>, and Rafiq Khanani<sup>2,3,4,5</sup>

<sup>1</sup>Karachi Institute of Radiotherapy and Nuclear Medicine (KIRAN), Karachi

<sup>2</sup>Advanced Laboratories, Karachi

<sup>3</sup>Department of Molecular Pathology, Hashmanis Group of Hospitals, Karachi

<sup>4</sup>Citilab Diagnostic Center, Karachi

<sup>5</sup>Global Research and Reference Labs, Karachi

\*Corresponding author

Email: [hanifmuhammad@hotmail.com](mailto:hanifmuhammad@hotmail.com) (MH)

## 21 **Abstract**

22 COVID-19 pandemic has been evolving in Pakistan since the UK, South African and Brazilian  
23 variants have started surfacing which are known for increase transmissibility and can also be  
24 responsible for escape from immune responses. The gold standard to detect these variants of  
25 concern is sequencing, however routine genomic surveillance in resource limited countries like  
26 Pakistan is not always readily available. With the emergence of variants of concern and a dearth  
27 of facilities for genomic scrutiny leaves policy makers and health authorities an inconsistent and  
28 twisted image to make decisions. The inadvertent detection of B.1.1.7 by target failure because  
29 of a key deletion in spike  $\Delta 69-70$  in the UK by commercially available COVID-19 PCR assay helps  
30 to understand target failures as an alternative approach to detect variants. It was ascertained  
31 further that a deletion in the ORF1a gene (ORF1a  $\Delta 3675-3677$ ) found common in B.1.1.7, B.135  
32 and P.1 variants of concern. The Real Time Quantitative PCR (RT-qPCR) assay for detection of  
33 emergence and spread of SARS-CoV-2 variants, by these target failures is used here. The  
34 positive samples archived in respective labs were divided in two groups used in the present  
35 study. Group I constitutes 261 positive samples out of 16964 (1.53%) collected from August till  
36 September 2020. Group II include 3501 positive samples out of 46041 (7.60%) from November  
37 2020 till January 2021. In positive samples of group I, no variant of concern was found. A  
38 staggering difference in results was noted in group II where positivity ratio increased  
39 exponentially and the variants of concern started appearing in significant numbers (53.64%  
40 overall). This is indicative that the third wave in Pakistan is due to the importation of SARS-CoV-  
41 2 variants. This calls for measures to increase surveillance by RT-qPCR which would help  
42 authorities in decision making.

## 43 Introduction

44 The global outbreak of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2),  
45 causative agent of COVID-19 disease, has ravaged the world by surprise. As of March 28, 2021  
46 the SARS-CoV-2 related infections have surpassed over 128,247,719 and 2,804,719 deaths  
47 globally. In Pakistan, the virus has affected more than 659,116 individuals, with more than  
48 14,256 reported deaths till date [1]. SARS-CoV-2 has been responsible for overwhelmed health  
49 care systems, coerced shutting down of schools and gatherings, and pulling the planet into an  
50 economic recession. Despite the fact that 2020 was a challenging year, 2021 seems to be not  
51 easy with the surfacing of multiple variants of SARS-CoV-2.

52 One of the notorious variants of SARS-CoV-2 characterized as 501Y.V1 (lineage B.1.1.7)  
53 becomes known in the United Kingdom in December 2020, [2]. Spreading like a wildfire B.1.1.7  
54 variant has reported to be rapidly expanding to 101 countries as of March 18, 2021 [3]. A  
55 similar pattern of staggering rise in SARS-CoV-2 related infections was observed in South Africa  
56 mainly due to the emergence of 501Y.V2 (lineage B.1.351) [4]. The increased transmission rates  
57 of both the variants are attributed to the mutation in receptor binding site (N501Y) of spike  
58 protein [5]. The 501Y.V2 variant presents a possible immune escape to antibodies by having  
59 two additional mutations in the spike protein (E484K and K417N) [6]. Moreover, It was reported  
60 in a concerning development that a different set of mutations (N501Y, E484K, and K417T)  
61 started surfacing in a new 501Y.V3 (P.1) variant of SARS-CoV-2 in Brazil [7].

62 First cases of Covid-19 in Pakistan were reported on Feb 26, 2020 which was the beginning of  
63 the arbitrary first wave that reached its peak on June 14 with 7000 cases per day and touched

64 the low 264 cases on August 29, 2020 with trough maintained till Oct 14, 2020 which  
65 hallmarked the beginning of so called second wave. Peak of the second wave reached on  
66 December 7 with 3795 reported new infections followed by a trough on February 16, 2021 with  
67 747 new cases per day which was not a true trough and this decline was followed by a gradual  
68 rise in daily new cases arbitrarily labeled as the third wave (Fig 1) with its new spike of 4767  
69 cases on March 28, 2021 [8].

70 **Fig 1: Daily record of cases of Novel Coronavirus (SARS-CoV-2).** Fig 1 representing three peaks  
71 of SARS-CoV-2, first achieved in June 2020 followed by trough from Aug to Oct 2020. Second  
72 peak started from November and after a brief stagnant phase, the cases started to increase  
73 exponentially in March due to emergence of SARS-CoV-2 variants.

74 The current emergence of SARS-CoV-2 variants following the phase of genetic stability of the  
75 virus is a matter of great concern since numerous new escape variants could surface in future  
76 and can head to epidemic resurgence, as seen in other countries. Increase in transmission of  
77 the virus augment chances for the emergence of SARS-CoV-2 variants. While sequencing is the  
78 gold standard to ascertain, it cannot always be scaled right away in limited resource countries  
79 for detection of variants of concern. Therefore a multiplex qPCR assay reported earlier to  
80 detect variants of concern is used here, this can be helpful in rapid mapping of SARS-CoV-2  
81 variants in countries like Pakistan (9).

## 82 **Materials & methods**

### 83 **Ethical approval**

84 The study was approved by Ethical Review Committee at Karachi Institute of Radiotherapy and  
85 Nuclear Medicine (KIRAN), Karachi, Pakistan.

## 86 **Sampling of SARS-CoV-2**

87 Nasopharyngeal and oropharyngeal specimens collected for testing of SARS-CoV-2 by reverse  
88 transcription (RT) polymerase chain reaction (RT-qPCR). This was achieved in Molecular  
89 pathology section of Advanced Laboratories, Hashmanis Laboratories, and Citilab Diagnostic  
90 Centers in Karachi. The samples which came positive were archived in respective labs and were  
91 used in the present study for variant detection. Briefly, positive samples were extracted using  
92 viral Nucleic acid kit (Systaac) according to manufacturers' instruction. The extracts were then  
93 subjected to RT-qPCR. The samples before extraction were divided in two categories, samples  
94 collected and archived from August to October 2020 (group I) and the samples collected from  
95 November 2020 to January 2021 (group II) respectively.

## 96 **Primers/ Probes**

97 The primers/ probes set CDC\_N1,  $\Delta 69/70$  del, and  $\Delta ORF1a$ -del (Table 1) were used in the assay  
98 to detect all the three variants by targeting the  $\Delta 3675$ -3677 SGF deletion in the ORF1a gene  
99 (not been reported in other SARS-CoV-2 lineages) and by targeting the  $\Delta 69/70$  HV deletion in  
100 the spike gene. This protocol can discriminate B.1.1.7 from B.1.351 and P.1. The 100  $\mu$ M stock  
101 solutions of primers/ probes were prepared for further processing.

102 **Table 1: Primers/probes sequences used in multiplex RT-qPCR for detection of SARS-CoV-2 variants**

Set Name	Primers/ Probes	Sequence
CDC_N1	Fwd Primer	GACCCCAAATCAGCGAAAT

	Rev Primer	TCTGGTACTGCCAGTTGAATCTG
	Probe	FAM- ACCCCGCATTACGTTTGGTGGACC- BHQ1
Yale_69/70del	Fwd Primer	TCAACTCAGGACTTGTTCTTACCT
	Rev Primer	TGGTAGGACAGGGTTATCAAAC
	Probe	HEX- TTCCATGCTATACATGTCTCTGGGA- BHQ1
Yale_ORF1a-del	Fwd Primer	TGCCTGCTAGTTGGGTGATG
	Rev Primer	TGCTGTCATAAGGATTAGTAACACT
	Probe	Cy5- GTTTGTCTGGTTTTAAGCTAAAAGACTGTG- BHQ2

103 Table 1: Listed are three primer-probe sets used to target the nucleocapsid (N1) gene on FAM,  
 104 spike  $\Delta$ 69-70 deletion on HEX, and ORF 1a  $\Delta$ 3675-3766 deletion of Cy5 fluorophores  
 105 respectively.

## 106 Multiplex RT-qPCR

107 The multiplex RT-qPCR assay used here was reported earlier by Vogels *et al.*, (2021) [9]. Briefly,  
 108 for PCR reaction a probe qPCR master mix along with hot start RT enzyme mix (Thermo  
 109 Scientific) is used. For PCR reaction 20  $\mu$ M of working stocks of primers/ probes mix was  
 110 prepared using 100  $\mu$ M stocks. After preparation of mix, the thermal cycler was set for FAM,  
 111 HEX, and Cy5 fluorophores while the thermal cycling conditions were slightly modified for  
 112 optimized results (Table 2).

113 **Table 2 : Thermal cycling programming on Bio-Rad CFX-96 for RT-qPCR detection of SARS-**  
 114 **CoV-2 variants.**

Step	Temperature	Time
------	-------------	------

1	50°C	20 minutes
2	95°	15 minutes
3	95°	12 seconds
4	55°	30 seconds
5	Read Plate	

} 42 cycles

115 Table 2: Thermal cycler condition were reverse transcription (step 1), initial denaturation for 15  
 116 minutes (step 2) followed by 42 cycles of denaturation, annealing and plate read (step 3-5).

## 117 Interpretation

118 All positive samples, subjected to the above mentioned RT-qPCR assay were analyzed and  
 119 interpreted as exhibited in Table 3.

120 **Table 3: Interpretation of results of RT-qPCR assay for SARS-CoV-2 variants**

Interpretation	CDC_N1	Δ69/70del	Δ3675-3766 del
Potentially B.1.1.7	CT ≤ 35	Undetected	Undetected
Potentially B.1351 or P.1	CT ≤ 35	CT ≤ 35	Undetected
Potentially B.1375	CT ≤ 35	Undetected	CT ≤ 35
Other lineages	CT ≤ 35	CT ≤ 35	CT ≤ 35

121 Table 3: Differentiation among the variants of concern is based on the target failure of spike  
 122 (Δ69/70) and ORF1a (Δ3675-3677) deletion.

123

## 124 Results

125 The total tests in group I were 16964 out of which positive cases were 261(1.53%). In group II  
 126 46041 tests were performed and the positive samples were 3501(7.60%) (Table 4). Mean age of  
 127 the individuals in group I was 38.01 ( $\pm 16.403$ ), and in group II 34.05 ( $\pm 15.219$ ) (Table 5). Only 58  
 128 out of 261 positive samples in group I were female (22.22%) and in group II 950 out of 3501 were female  
 129 (27.01%).

130 **Table 4: Scenario of SARS-CoV-2 B.1.1.7, B.1.351, and P.1 variants of concern in Karachi,**  
 131 **Pakistan**

132

	Period selected for analysis	Total #of samples received for RT-qPCR testing	Total # of PCR positive samples	Percentage of PCR positive samples	Scenario of SARS-CoV-2 B.1.1.7, B.1.351, and P.1 variants of concern in Karachi		
					B.1.1.7	B.1.351 & P.1	Other lineages
	August	4638	90	1.94%	0	0	90
	September	5833	69	1.182%	0	0	69
	October	6493	102	1.57%	0	0	102
Group I		16964	261	1.538%	0	0	261
	November	9233	610	6.60%	164(26.88%)	68(11.14%)	378(61.96%)
	December	19299	1682	8.71%	474(28.18%)	484(28.77%)	724(43.04%)
	January	17509	1209	6.90%	326(26.96%)	362(29.94%)	521(43.09%)
Group II		46041	3501	7.60%	944(26.96%)	934(26.67%)	1623(46.3%)

133 Table 4: Describes the total number of samples in group I and group II, percentage of positive  
 134 samples in both groups and the occurrence of variants of concern in both groups. Data in group  
 135 I indicates the low positivity ratio and non existence of variants of concern. In group II positivity  
 136 ratio increased significantly and the ratio of variants of concern is very high and almost semi of  
 137 the other lineages.

138 **Table 5: Demography of sample population and the variants of concern in Karachi, Pakistan**

	Total #of samples for RT-qPCR testing	Total # of PCR positive samples	Positivity percentage	Male to Female ratio		Mean age
				Male	Female	
Group I	16964	261	1.538%	77.85%	22.15%	38.01 (±16.403)
Group II	46041	3501	7.60%	72.99	27.01%	34.05 (±15.219)

139 Table 5: Describe the gender, age and positivity ratio in group I and group II.

140 SARS-CoV-2 variants of concerned were detected by target failures using a multiplex RT-qPCR.  
 141 A descriptive RT-qPCR amplification graph is shown in Fig 2. Group I was screened and none of  
 142 variants of concern were found to be present (All targets amplified). In group II significant  
 143 difference noted from group I, the results showed a total of 944 (26.96%) showed double target  
 144 failure of Δ69-70 as well as Δ3675-3766 del which is indicative of B.1.1.7 variant of concern (UK  
 145 variant). A rather significant number 934 (26.67%) samples exhibited single target failure  
 146 Δ3675-3766-del implied presence of B.135 and P.1 variant of concern. While 1623 (46.30%)  
 147 samples did not show any failure of target and represent other lineages.

148 **Fig 2. RT-qPCR graphical representation of ORF1a and spike target failure to discriminate**  
149 **B.1.1.7, B.135, P.1 and other lineages of SARS-CoV-2.** Fig 2. (A) exhibit double target failure by  
150 ORF1a  $\Delta$ 3675-3677 and spike  $\Delta$ 60-70 deletions, indicative of potential B.1.1.7. (B) shows  
151 potential B.135 and P.1 variants of SARS-CoV-2 by ORF 1a target failure. (C) All three targets of  
152 the multiplex RT-qPCR demonstrate no target failure and lineages other than variants of  
153 concern.

## 154 **Discussion**

155 The PCR tests for SARS-CoV-2 detection in UK during September 2020 have shown unusual  
156 SARS-CoV-2 strain that prevents amplification of spike gene, also known as spike gene target  
157 failure (SGTF), in a commercially available kit [10]. The failure to detect spike gene is attributed  
158 to a  $\Delta$ 69/70 HV deletion as in the lineage 501.YV1 (B.1.1.7) or commonly known as the UK  
159 variant. Moreover, the P.1. lineage in Brazil and the B.1.351 lineage described in South Africa  
160 share a common set of mutations ORF1a deletion 3675-3677 SGF [11]. Therefore, a sample with  
161  $\Delta$ 69/70 HV deletion is not enough for discriminative detection of B.1.1.7 from other variants of  
162 concern i.e.501.YV2 and 501.YV3 (B.1351; South African and P.1; Brazilian variant), which does  
163 not possess  $\Delta$ 69/70 HV deletion. Therefore, a multiplex PCR assay reported earlier targeting  
164  $\Delta$ 3675-3677 SGF deletion in ORF 1a gene along with  $\Delta$ 69/70 HV deletion is used in the present  
165 study to discriminate B.1.1.7 from B.1351 and P.1 variants of SARS-CoV-2[9]. We have used  
166 CDC\_N1 primer and probe as a control to ensure that target failures were due to these  
167 mutations. In resource limited countries like Pakistan the present study can therefore be  
168 helpful to rapidly scale up the prediction of SARS-CoV-2 variants.

169 These SARS-CoV-2 variants (B.1.1.7, B.1.351 and P.1) are the cause of concern globally not only  
170 because of their ability to transmit rapidly but also because of antigenic changes due to  
171 multiple mutations in spike protein region unfavorable to monoclonal antibody (mAB) therapies  
172 and protection by vaccines [7, 12]. The variant P.1 or 501Y.V3 is spreading at a rapid pace in  
173 Brazil and spreading globally. N501Y is the common mutation shared between these three  
174 SARS-CoV-2 lineages of concern. This particular mutation may result in augmented binding to  
175 ACE231 which exhibit no significant escape value from emergency use authorized mAB  
176 therapies and vaccines [13]. However, E484K mutation present in B.135 and P.1 variants has  
177 been attributed for impairing many mABs and vaccines under development and also  
178 responsible for re-infection [10]. This threat has been augmented by the recent observation  
179 from the Novavax vaccine trial in South Africa which showed that exposure to B.135 in placebo  
180 recipients' exhibit to be un-protective against prior SARS-CoV-2 infection [12-14]. Even in Brazil  
181 the same mutation in P.1 is reported to be responsible for spreading of the virus in a population  
182 that was already 76% seropositive due to past infection [14]. This highlights the importance of  
183 this study of mapping viral variants by RT-qPCR which could be adopted by limited resource  
184 countries worldwide. This mapping would be helpful in effective development of therapies and  
185 vaccines targeting antigenically distinct epitopes.

186 We demonstrate the presence of UK (B.1.1.7; 27.04%) and South African and Brazilian (B.135  
187 and P.1; 29.94%) variants of SARS-CoV-2 from the positive samples collected in group II. the  
188 present study positive samples archived before November 2020, i.e. in group I, did not exhibit  
189 variants of concern. Noteworthy, in group I (Aug to Oct 2020) the positivity ratio was 1.538%  
190 which later increased to 7.60% in group II (Nov 2020 to Jan 2021) which clearly indicate the

191 importation of cases from countries where these viral strains were spreading before and during  
192 November 2020. The spread of pandemic globally provides opportunity for variable strain types  
193 to thrive. One of the reasons of this spread could be the unmonitored international flights and  
194 no quarantine on arrival in Pakistan from any country, which lead to a rapid introduction of  
195 variants of concern in Pakistan [15-16]. Pakistan is in second wave which could not be truncated  
196 due to variants entry which prevented decline to base line following the first wave and second  
197 peak of second wave is labeled as 3<sup>rd</sup> wave affecting Prime minister, First Lady and President of  
198 Pakistan. Not only the notables of the country have been affected in this notorious second  
199 wave, but our results also revealed that positivity ratio in female has significantly increased  
200 from 22.15% to 27.01%. This clearly indicates that variants are more transmittable.

201 At present, the significance of the surveillance of variants has increased globally as the  
202 vaccination jabs have started and countries are in race to vaccinate. Limited resources countries  
203 are lagging behind and with the emergence of these variants in these countries it is of high  
204 possibility that an escape variant could evolve which could hinder the vaccination process  
205 globally. The limited resource countries might act as the breeding ground for the variants of the  
206 virus that could be detrimental to global efforts for ending the pandemic.

207 The striking part of our study is the presence of variant with  $\Delta 3675-3677$  SGF deletion in ORF 1a  
208 gene which implied the presence of South African and Brazilian variants in Pakistan. The most  
209 detrimental part of the present study is that South African and Brazilian variants are  
210 comparable in numbers in December 2020 and January 2021 as compared to its counterpart UK  
211 variant, while SARS-CoV-2 with lineages other than the variants of concern are less in numbers  
212 in positive samples collected during and after November 2020. The emergence of the UK, South

213 African and Brazilian variants calls for strict measures to curb the spread of SARS-CoV-2. The  
214 lucidity in this situation of darkness can only be attained by arrangement of non-  
215 pharmaceutical interventions and scaling up-of vaccination program, which could lead to fewer  
216 infections, in turn leads to fewer variants. Both strategies are important until population  
217 immunity is achieved globally.

218 The current pandemic should nudge the developed countries that infectious diseases have a  
219 profound impact on lives and economies and rapid distribution and implementation of useful  
220 vaccines against these infections should remain priority. The cooperation of the globe to make  
221 certain the justness and responsiveness to local contexts is necessary on the complex trail  
222 forward to ending the COVID-19 pandemic.

## 223 **Acknowledgements**

224 Authors acknowledge support from IT departments of Advanced Laboratories, Hashmanis  
225 group of hospital and Citilab diagnostic center for their support in providing SARS-CoV-2 data.

## 226 **References**


- 227 1. COVID-19 Health Advisory Platform by Ministry of National Health Services Regulations  
228 and Coordination <https://covid.gov.pk/>
- 229 2. England PH. Investigation of novel SARS-CoV-2 variant: variant of concern 202012/01,  
230 technical briefing 3. Public Health England, London, United Kingdom. 2020.
- 231 3. Global initiative on sharing all influenza data (GISAID) [https://www.gisaid.org/hcov19-](https://www.gisaid.org/hcov19-variants/)  
232 variants/



- 233 4. Hsiao M, Davies MA, Kalk E. SARS-CoV-2 seroprevalence in the Cape Town Metropolitan  
234 sub-districts after the peak of infections. *NICD COVID-19 Special Public Health Surveill*  
235 *Bull.* 2020 Sep 28;18:1-9.
- 236 5. Gu H, Chen Q, Yang G, He L, Fan H, Deng YQ, Wang Y, Teng Y, Zhao Z, Cui Y, Li Y.  
237 Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. *Science.* 2020 Sep  
238 25;369(6511):1603-7.
- 239 6. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, *et al.*  
240 SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma.  
241 *Nature medicine.* 2021 Mar 2:1-4.<https://doi.org/10.1101/2021.01.18.427166>
- 242 7. Faria NR, Claro IM, Candido D, Moyses Franco LA, Andrade PS, Coletti TM, Silva CA, Sales  
243 FC, Manuli ER, Aguiar RS, Gaburo N. Genomic characterization of an emergent SARS-  
244 CoV-2 lineage in Manaus: preliminary findings. *Virological.* 2021 Jan.
- 245 8. Worldometer. COVID-19 coronavirus pandemic country estimates: Pakistan.  
246 <https://www.worldometers.info/coronavirus/country/pakistan/>
- 247 9. Vogels, C., Fauver, J. & Grubaugh, N. Multiplexed RT-qPCR to screen for SARS-COV-2  
248 B.1.1.7, B.1.351, and P.1 variants of concern  
249 v2. *protocols.io* (2021) doi: 10.17504/protocols.io.brrhm536
- 250 10. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, *et al.* Antibody Resistance of SARS-CoV-2  
251 Variants B. 1.351 and B. 1.1. 7. *Nature.* 2021 Jan 1;10.
- 252 11. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, *et al.*  
253 Emergence and rapid spread of a new severe acute respiratory syndrome-related

- 254 coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa.  
255 medRxiv. 2020 Jan 1. doi: <https://doi.org/10.1101/2020.12.21.20248640>
- 256 12. Naveca F, Nascimento V, Souza V, Corado A, Nascimento F, Silva G, *et al.* Phylogenetic  
257 relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants  
258 harboring mutations E484K and N501Y in the Spike protein. Virological. org. Available at:  
259 [https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-](https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-fromamazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585)  
260 [fromamazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-](https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-fromamazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585)  
261 [n501y-in the-spike-protein/585](https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-fromamazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585). 2021 Jan 11.
- 262 13. Voloch CM, da Silva Francisco R, de Almeida LG, Cardoso CC, Brustolini OJ, Gerber AL,  
263 Guimarães AP, Mariani D, da Costa RM, Ferreira OC, Workgroup CU. Genomic  
264 characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. Journal of  
265 Virology. 2021 Mar 1.
- 266 14. Sabino EC, Buss LF, Carvalho MP, Prete CA, Crispim MA, Fraiji NA, Pereira RH, Parag KV,  
267 da Silva Peixoto P, Kraemer MU, Oikawa MK. Resurgence of COVID-19 in Manaus, Brazil,  
268 despite high seroprevalence. The Lancet. 2021 Feb 6;397(10273):452-5.
- 269 15. Mukry SN, Ahmed S, Bukhari AR, Shahni A, Sufaida G, Naz A, Shamsi TS. Sequencing of  
270 SARS CoV2 in local transmission cases through oxford nanopore MinION platform from  
271 Karachi Pakistan. bioRxiv. 2021 Jan 7:2021-01.
- 272 16. Umair M, Ikram A, Salman M, Alam MM, Badar N, Rehman Z, Tamim S, Khurshid A, Ahad  
273 A, Ahmad H, Ullah S. Importation of SARS-CoV-2 Variant B. 1.1. 7 in Pakistan. Journal of  
274 Medical Virology. 2021 Feb 11. <https://doi.org/10.1002/jmv.26869>.

# Daily New Cases

Cases per Day  
Data as of 0:00 GMT+0



**A****Amplification****B****Amplification****C****Amplification**